



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India

Tel : (02646) 220774

Fax : (02646) 251291

Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.

Tel : (91-22) 26701050/1/2

Fax : (91-22) 26701053

Email: contact@samratpharmachem.in

May 30, 2019

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of the Board Meeting of the Company held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, May 30, 2019, the Board has considered and adopted the attached Audited Financial Results of the Company for the year ended March 31, 2019, which is enclosed herewith along with the Auditor's Report and Declaration for Unmodified Opinion on the Financial Results of the Company.

The meeting of the Board of Directors of the Company commenced at 18:00 hrs and concluded at 19:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,

For Samrat Pharmachem Limited

Sandeep Prajapati
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)

Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)

(Rs. in Lakhs)						
Statement of Standalone Audited Results for the Quarter and for the Year Ended 31 MARCH, 2019						
Particulars	Year to Date 31-Dec-18 (Unaudited)	Quarter Ended		Year Ended		
		31-Mar-19 (Audited)	31-Dec-18 (Unaudited)	31-Mar-18 (Audited)	31-Mar-19 (Audited)	31-Mar-18 (Audited)
1 (a). Revenue from Operations	7,470.76	3,642.88	2,737.47	2,644.73	11,113.64	9,252.01
(b). Other Income	28.05	17.62	3.93	16.35	45.67	24.57
Total Revenue	7,498.81	3,660.50	2,741.40	2,661.08	11,159.31	9,276.58
2. Expenses						
a) Cost of materials consumed	7,132.70	3,220.54	2,438.17	2,453.33	10,353.24	8,110.77
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	131.97
c) Changes in inventories of FG, WIP & Stock in trade	(145.75)	54.82	99.86	(49.44)	(90.93)	(50.56)
d) Employee Costs	87.36	51.00	31.99	41.22	138.36	129.60
e) Finance Cost	71.67	34.17	26.55	24.78	105.84	86.35
f) Depreciation & Amortisation expense	31.37	10.40	10.63	8.89	41.77	41.22
g) Other Expenses	275.26	120.01	96.60	57.58	395.27	335.21
Total Expenses	7,452.61	3,490.94	2,703.80	2,536.36	10,943.55	8,784.56
3. Profit before exceptional items and tax	46.20	169.56	37.60	124.72	215.76	492.02
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5. Profit before tax	46.20	169.56	37.60	124.72	215.76	492.02
6. Tax expense						
a) Current Tax	(8.06)	(53.40)	(7.80)	(63.71)	(61.46)	(168.94)
b) Deferred Tax	(14.67)	13.92	(1.47)	9.24	(0.75)	(1.41)
Total Tax Expense	(22.73)	(39.48)	(9.27)	(54.47)	(62.21)	(170.35)
7. Profit (Loss) for the period from continuing operations	23.47	130.08	28.33	70.25	153.55	321.67
8. Profit / (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
9. Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
10. Profit / (Loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Profit / (Loss) for the period	23.47	130.08	28.33	70.25	153.55	321.67
12. Other Comprehensive Income (OCI)	0.00	0.00	0.00	0.00	0.00	0.00
13. Total Comprehensive Income for the period	23.47	130.08	28.33	70.25	153.55	321.67
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
15. Earnings per equity share (not annualized)						
a) Basic	0.76	4.21	0.92	2.27	4.97	10.41
b) Diluted	0.76	4.21	0.92	2.27	4.97	10.41



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Standalone Statement of Assets and Liabilities		
Particulars	As at 31-Mar-19 (Audited)	As at 31-Mar-18 (Audited)
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	683.54	695.96
Capital work-in-progress	0.00	0.00
Intangible assets	2.76	2.66
Intangible assets under development	0.00	0.00
Financial Assets		
Investments	0.00	0.00
Loans	9.68	8.71
Deferred tax assets (net)	0.00	0.00
Other non-current assets	50.82	48.88
Total Non Current Assets	746.80	756.21
Current Assets		
Inventories	792.96	684.62
Financial Assets		
Investments	0.10	0.10
Trade Receivables	2,104.79	2,188.61
Cash and Cash Equivalents	224.62	398.11
Loans	2.46	2.26
Other Financial Assets	0.00	0.00
Other current assets	150.93	52.85
Total Current Assets	3,275.86	3,326.55
Total Assets	4,022.66	4,082.76
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	308.97	308.97
Other Equity	1,697.72	1,544.16
Total Equity	2,006.69	1,853.13
Non-Current Liabilities		
Financial Liabilities		
Borrowings	31.28	76.21
Provisions	0.00	0.00
Deferred Tax Liabilities (Net)	32.17	31.42
Other Non-Current Liabilities	19.63	19.63
Total Non-Current liabilities	83.08	127.26
Current Liabilities		
Financial Liabilities		
Borrowings	577.16	822.24
Trade Payables	1,265.63	1,039.50
Other Financial Liabilities	0.00	0.00
Other Current Liabilities	53.40	99.54
Provisions	36.70	141.09
Total Current Liabilities	1,932.89	2,102.37
Total Liabilities	4,022.66	4,082.76



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Notes

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Thursday, 30 May 2019 at the Corporate Office of the Company.
3. The figures of the quarter ended 31 Mar 2019 and 31 Mar 2018 are the balancing figures between the audited figures in respect of full financial years and the published (unaudited) up to the third quarter of relevant financial year.
4. The Company manufactures pharmaceutical chemicals, which is a single business segment.
5. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

By order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director



Place : Mumbai
Date : 30 May 2019



Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance

CA Nihar Dharod
Indirect Tax & Litigation

Independent Auditor's Report on Quarterly Financial Results and Year to Date Results of Samrat Pharmachem Ltd Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Samrat Pharmachem Limited**

We have audited the financial results of Samrat Pharmachem Limited for the year ended 31st March 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Attention is drawn to the fact that the figures for the quarter ended 31st March 2019 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the end of third quarter of the current and previous financial year respectively. Also the figures upto the end of the third quarter for the current and previous financial year had only been reviewed and not subjected to audit.

These financial results are based on the financial statements for the year ended 31 March 2019 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 ('the Act') and published year to date figures up to the end of the third quarter of the financial year prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting, specified under Section 133 of the Act, and SEBI Circular CIRICFD/FAC/62/2016 dated 5 July 2016, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of the financial statements for the year ended 31 March 2019 and our review of financial results for the nine-month period ended 31 December 2018.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis of our opinion.




In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as year to date results:

- a. as presented in accordance with requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in this regard and
- b. give true and fair view of the net profit and other financial information for the quarter ended March 31, 2019 as well as the year to date results for the period from 01st April 2018 to 31st March 2019.

For Shah & Savla LLP

Chartered Accountants

FRN:109364W



**MIRAL H. NAGDA
(PARTNER)**

Membership No. 108135



Place: Mumbai

Date : 30th May 2019



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India

Tel : (02646) 220774

Fax : (02646) 251291

Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.

Tel : (91-22) 26701050/1/2

Fax : (91-22) 26701053

Email: contact@samratpharmachem.in

30 May, 2019

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Sub: Declaration with respect to Audit report with unmodified opinion for the financial year ended March 31, 2019

Dear Sir,

Pursuant to clause 4.1 of SEBI circular no CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the company M/s Shah & Savla LLP, Chartered Accountants, Mumbai, have issued the audit report under the Companies Act 2013 on the Standalone Financial Results of the Company as prepared under SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 for the financial year ended March 31, 2019, with unmodified opinion.

Request to take note of the above

Thanking You.

Yours faithfully,
For Samrat Pharmachem Limited

Sandeep Prajapati
Company Secretary & Compliance Officer